GlassScriptPhysician profile
Kenneth John Carbone
NPI 1649482936
$23,864.02
in general payments reported to CMS, 2019-2025
77 companies · $3,581 in 2025
The $3,581 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,410 · 2020: $2,669 · 2021: $3,443 · 2022: $3,327 · 2023: $3,661 · 2024: $3,772 · 2025: $3,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,014.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,175.67 | 2019-2025 | Vraylar, Ubrelvy, Synthroid |
| Astrazeneca Pharmaceuticals LP | $2,231.68 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,906.03 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $1,670.41 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,429.38 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $1,159.33 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $1,092.11 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $1,043.24 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $714.04 | 2019-2025 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $692.38 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $651.84 | 2019-2025 | Verquvo, Gardasil 9, Vaxelis |
| E.R. Squibb & Sons, L.L.C. | $577.80 | 2019-2025 | Eliquis, Camzyos |
| Astellas Pharma US INC | $557.27 | 2019-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $439.68 | 2019-2022 | |
| Allergan, INC. | $425.02 | 2019-2020 |
Show all 77 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Carbone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.